Rapastinel (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rapastinel" in Spanish language version.

refsWebsite

Global rank Spanish rank

4^th place

4^th place

2^nd place

2^nd place

57^th place

3^rd place

5semanticscholar.org

11^th place

79^th place

2prnewswire.com

406^th place

666^th place

6^th place

5^th place

1clinicaltrialsarena.com

low place

low place

49^th place

100^th place

low place

low place

archive.org (Global: 6^th place; Spanish: 5^th place)

Burgdorf, Jeffrey; Zhang, Xiao-lei; Weiss, Craig; Matthews, Elizabeth; Disterhoft, John F.; Stanton, Patric K.; Moskal, Joseph R. (2011). «The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats». Neurobiology of Aging 32 (4): 698-706. ISSN 0197-4580. PMC 3035742. PMID 19446371. doi:10.1016/j.neurobiolaging.2009.04.012.
Burgdorf, Jeffrey; Zhang, Xiao-lei; Weiss, Craig; Matthews, Elizabeth; Disterhoft, John F.; Stanton, Patric K.; Moskal, Joseph R. (2011). «The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats». Neurobiology of Aging 32 (4): 698-706. PMC 3035742. PMID 19446371. doi:10.1016/j.neurobiolaging.2009.04.012.

clinicaltrialsarena.com (Global: low place; Spanish: low place)

«Allergan’s depression drug fails in Phase III trials». Clinical Trials Arena. 7 de marzo de 2019.

doi.org (Global: 2^nd place; Spanish: 2^nd place)

dx.doi.org

Henter, Ioline D.; Park, Lawrence T.; Zarate, Carlos A. (May 2021). «Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status». CNS Drugs 35 (5): 527-543. ISSN 1179-1934. PMC 8201267. PMID 33904154. doi:10.1007/s40263-021-00816-x.
Moskal JR, Burgdorf JS, Stanton PK, Kroes RA, Disterhoft JF, Burch RM, Amin Khan M (2016). «The Development of Rapastinel (Formerly GLYX-13); a rapid acting and long lasting antidepressant». Curr Neuropharmacol 15 (1): 47-56. PMC 5327451. PMID 26997507. doi:10.2174/1570159x14666160321122703.
Henter, Ioline D.; Park, Lawrence T.; Zarate, Carlos A. (May 2021). «Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status». CNS Drugs 35 (5): 527-543. ISSN 1179-1934. PMC 8201267. PMID 33904154. doi:10.1007/s40263-021-00816-x.
Preskorn, Sheldon; Macaluso, Matthew; Mehra, D. O. Vishaal; Zammit, Gary; Moskal, Joseph R.; Burch, Ronald M.; GLYX-13 Clinical Study Group (March 2015). «Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent». Journal of Psychiatric Practice 21 (2): 140-149. ISSN 1538-1145. PMID 25782764. S2CID 36800194. doi:10.1097/01.pra.0000462606.17725.93.
Haring R, Stanton PK, Scheideler MA, Moskal JR (1991). «Glycine-like modulation of N-methyl-D-aspartate receptors by a monoclonal antibody that enhances long-term potentiation». J. Neurochem. 57 (1): 323-32. PMID 1828831. S2CID 37941813. doi:10.1111/j.1471-4159.1991.tb02131.x.
Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, Harris RB, Disterhoft JF (2005). «GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator». Neuropharmacology 49 (7): 1077-87. PMID 16051282. S2CID 7372648. doi:10.1016/j.neuropharm.2005.06.006.
Burgdorf, Jeffrey; Zhang, Xiao-lei; Weiss, Craig; Matthews, Elizabeth; Disterhoft, John F.; Stanton, Patric K.; Moskal, Joseph R. (2011). «The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats». Neurobiology of Aging 32 (4): 698-706. ISSN 0197-4580. PMC 3035742. PMID 19446371. doi:10.1016/j.neurobiolaging.2009.04.012.
Pothula, Santosh; Liu, Rong-Jian; Wu, Min; Sliby, Alexa-Nicole; Picciotto, Marina R.; Banerjee, Pradeep; Duman, Ronald S. (March 2021). «Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons». Neuropsychopharmacology 46 (4): 799-808. ISSN 1740-634X. PMC 8027594. PMID 33059355. doi:10.1038/s41386-020-00882-7.
Zhang, Xiao-lei; Sullivan, John A.; Moskal, Joseph R.; Stanton, Patric K. (December 2008). «A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus». Neuropharmacology 55 (7): 1238-1250. ISSN 0028-3908. PMC 2661239. PMID 18796308. doi:10.1016/j.neuropharm.2008.08.018.
Pothula, Santosh; Kato, Taro; Liu, Rong-Jian; Wu, Min; Gerhard, Danielle; Shinohara, Ryota; Sliby, Alexa-Nicole; Chowdhury, Golam M. I. et al. (September 2021). «Cell-type specific modulation of NMDA receptors triggers antidepressant actions». Molecular Psychiatry 26 (9): 5097-5111. ISSN 1476-5578. PMID 32488125. doi:10.1038/s41380-020-0796-3.
Kato, Taro; Duman, Ronald S. (January 2020). «Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms». Pharmacology, Biochemistry, and Behavior 188: 172827. ISSN 1873-5177. PMID 31733218. doi:10.1016/j.pbb.2019.172827.
Burgdorf, Jeffrey; Zhang, Xiao-lei; Weiss, Craig; Matthews, Elizabeth; Disterhoft, John F.; Stanton, Patric K.; Moskal, Joseph R. (2011). «The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats». Neurobiology of Aging 32 (4): 698-706. PMC 3035742. PMID 19446371. doi:10.1016/j.neurobiolaging.2009.04.012.
Moskal, Joseph R.; Kuo, Amy G.; Weiss, Craig; Wood, Paul L.; O'Connor Hanson, Amy; Kelso, Stephen; Harris, Robert B.; Disterhoft, John F. (2005). «GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulator». Neuropharmacology 49 (7): 1077-87. PMID 16051282. S2CID 7372648. doi:10.1016/j.neuropharm.2005.06.006.
Stanton, Patric K.; Potter, Pamela E.; Aguilar, Jennifer; Decandia, Maria; Moskal, Joseph R. (2009). «Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13». NeuroReport 20 (13): 1193-7. PMID 19623090. S2CID 6269255. doi:10.1097/WNR.0b013e32832f5130.
Stanton, Patric K.; Potter, Pamela E.; Aguilar, Jennifer; Decandia, Maria; Moskal, Joseph R. (2009). «Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13». NeuroReport 20 (13): 1193-7. PMID 19623090. doi:10.1097/WNR.0b013e32832f5130.

gateneuro.com (Global: low place; Spanish: low place)

«Home - Gate Neurosciences» (en inglés estadounidense). Consultado el 13 de mayo de 2022.

issn.org (Global: 57^th place; Spanish: 3^rd place)

portal.issn.org

Henter, Ioline D.; Park, Lawrence T.; Zarate, Carlos A. (May 2021). «Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status». CNS Drugs 35 (5): 527-543. ISSN 1179-1934. PMC 8201267. PMID 33904154. doi:10.1007/s40263-021-00816-x.
Henter, Ioline D.; Park, Lawrence T.; Zarate, Carlos A. (May 2021). «Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status». CNS Drugs 35 (5): 527-543. ISSN 1179-1934. PMC 8201267. PMID 33904154. doi:10.1007/s40263-021-00816-x.
Preskorn, Sheldon; Macaluso, Matthew; Mehra, D. O. Vishaal; Zammit, Gary; Moskal, Joseph R.; Burch, Ronald M.; GLYX-13 Clinical Study Group (March 2015). «Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent». Journal of Psychiatric Practice 21 (2): 140-149. ISSN 1538-1145. PMID 25782764. S2CID 36800194. doi:10.1097/01.pra.0000462606.17725.93.
Burgdorf, Jeffrey; Zhang, Xiao-lei; Weiss, Craig; Matthews, Elizabeth; Disterhoft, John F.; Stanton, Patric K.; Moskal, Joseph R. (2011). «The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats». Neurobiology of Aging 32 (4): 698-706. ISSN 0197-4580. PMC 3035742. PMID 19446371. doi:10.1016/j.neurobiolaging.2009.04.012.
Pothula, Santosh; Liu, Rong-Jian; Wu, Min; Sliby, Alexa-Nicole; Picciotto, Marina R.; Banerjee, Pradeep; Duman, Ronald S. (March 2021). «Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons». Neuropsychopharmacology 46 (4): 799-808. ISSN 1740-634X. PMC 8027594. PMID 33059355. doi:10.1038/s41386-020-00882-7.
Zhang, Xiao-lei; Sullivan, John A.; Moskal, Joseph R.; Stanton, Patric K. (December 2008). «A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus». Neuropharmacology 55 (7): 1238-1250. ISSN 0028-3908. PMC 2661239. PMID 18796308. doi:10.1016/j.neuropharm.2008.08.018.
Pothula, Santosh; Kato, Taro; Liu, Rong-Jian; Wu, Min; Gerhard, Danielle; Shinohara, Ryota; Sliby, Alexa-Nicole; Chowdhury, Golam M. I. et al. (September 2021). «Cell-type specific modulation of NMDA receptors triggers antidepressant actions». Molecular Psychiatry 26 (9): 5097-5111. ISSN 1476-5578. PMID 32488125. doi:10.1038/s41380-020-0796-3.
Kato, Taro; Duman, Ronald S. (January 2020). «Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms». Pharmacology, Biochemistry, and Behavior 188: 172827. ISSN 1873-5177. PMID 31733218. doi:10.1016/j.pbb.2019.172827.

nih.gov (Global: 4^th place; Spanish: 4^th place)

ncbi.nlm.nih.gov

Henter, Ioline D.; Park, Lawrence T.; Zarate, Carlos A. (May 2021). «Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status». CNS Drugs 35 (5): 527-543. ISSN 1179-1934. PMC 8201267. PMID 33904154. doi:10.1007/s40263-021-00816-x.
Moskal JR, Burgdorf JS, Stanton PK, Kroes RA, Disterhoft JF, Burch RM, Amin Khan M (2016). «The Development of Rapastinel (Formerly GLYX-13); a rapid acting and long lasting antidepressant». Curr Neuropharmacol 15 (1): 47-56. PMC 5327451. PMID 26997507. doi:10.2174/1570159x14666160321122703.
Henter, Ioline D.; Park, Lawrence T.; Zarate, Carlos A. (May 2021). «Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status». CNS Drugs 35 (5): 527-543. ISSN 1179-1934. PMC 8201267. PMID 33904154. doi:10.1007/s40263-021-00816-x.
Preskorn, Sheldon; Macaluso, Matthew; Mehra, D. O. Vishaal; Zammit, Gary; Moskal, Joseph R.; Burch, Ronald M.; GLYX-13 Clinical Study Group (March 2015). «Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent». Journal of Psychiatric Practice 21 (2): 140-149. ISSN 1538-1145. PMID 25782764. S2CID 36800194. doi:10.1097/01.pra.0000462606.17725.93.
Haring R, Stanton PK, Scheideler MA, Moskal JR (1991). «Glycine-like modulation of N-methyl-D-aspartate receptors by a monoclonal antibody that enhances long-term potentiation». J. Neurochem. 57 (1): 323-32. PMID 1828831. S2CID 37941813. doi:10.1111/j.1471-4159.1991.tb02131.x.
Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, Harris RB, Disterhoft JF (2005). «GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator». Neuropharmacology 49 (7): 1077-87. PMID 16051282. S2CID 7372648. doi:10.1016/j.neuropharm.2005.06.006.
Burgdorf, Jeffrey; Zhang, Xiao-lei; Weiss, Craig; Matthews, Elizabeth; Disterhoft, John F.; Stanton, Patric K.; Moskal, Joseph R. (2011). «The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats». Neurobiology of Aging 32 (4): 698-706. ISSN 0197-4580. PMC 3035742. PMID 19446371. doi:10.1016/j.neurobiolaging.2009.04.012.
Pothula, Santosh; Liu, Rong-Jian; Wu, Min; Sliby, Alexa-Nicole; Picciotto, Marina R.; Banerjee, Pradeep; Duman, Ronald S. (March 2021). «Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons». Neuropsychopharmacology 46 (4): 799-808. ISSN 1740-634X. PMC 8027594. PMID 33059355. doi:10.1038/s41386-020-00882-7.
Zhang, Xiao-lei; Sullivan, John A.; Moskal, Joseph R.; Stanton, Patric K. (December 2008). «A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus». Neuropharmacology 55 (7): 1238-1250. ISSN 0028-3908. PMC 2661239. PMID 18796308. doi:10.1016/j.neuropharm.2008.08.018.
Pothula, Santosh; Kato, Taro; Liu, Rong-Jian; Wu, Min; Gerhard, Danielle; Shinohara, Ryota; Sliby, Alexa-Nicole; Chowdhury, Golam M. I. et al. (September 2021). «Cell-type specific modulation of NMDA receptors triggers antidepressant actions». Molecular Psychiatry 26 (9): 5097-5111. ISSN 1476-5578. PMID 32488125. doi:10.1038/s41380-020-0796-3.
Kato, Taro; Duman, Ronald S. (January 2020). «Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms». Pharmacology, Biochemistry, and Behavior 188: 172827. ISSN 1873-5177. PMID 31733218. doi:10.1016/j.pbb.2019.172827.
Burgdorf, Jeffrey; Zhang, Xiao-lei; Weiss, Craig; Matthews, Elizabeth; Disterhoft, John F.; Stanton, Patric K.; Moskal, Joseph R. (2011). «The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats». Neurobiology of Aging 32 (4): 698-706. PMC 3035742. PMID 19446371. doi:10.1016/j.neurobiolaging.2009.04.012.
Moskal, Joseph R.; Kuo, Amy G.; Weiss, Craig; Wood, Paul L.; O'Connor Hanson, Amy; Kelso, Stephen; Harris, Robert B.; Disterhoft, John F. (2005). «GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulator». Neuropharmacology 49 (7): 1077-87. PMID 16051282. S2CID 7372648. doi:10.1016/j.neuropharm.2005.06.006.
Stanton, Patric K.; Potter, Pamela E.; Aguilar, Jennifer; Decandia, Maria; Moskal, Joseph R. (2009). «Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13». NeuroReport 20 (13): 1193-7. PMID 19623090. S2CID 6269255. doi:10.1097/WNR.0b013e32832f5130.
Stanton, Patric K.; Potter, Pamela E.; Aguilar, Jennifer; Decandia, Maria; Moskal, Joseph R. (2009). «Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13». NeuroReport 20 (13): 1193-7. PMID 19623090. doi:10.1097/WNR.0b013e32832f5130.

pubmed.ncbi.nlm.nih.gov

Preskorn, Sheldon; Macaluso, Matthew; Mehra, D. O. Vishaal; Zammit, Gary; Moskal, Joseph R.; Burch, Ronald M.; GLYX-13 Clinical Study Group (March 2015). «Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent». Journal of Psychiatric Practice 21 (2): 140-149. ISSN 1538-1145. PMID 25782764. S2CID 36800194. doi:10.1097/01.pra.0000462606.17725.93.
Pothula, Santosh; Kato, Taro; Liu, Rong-Jian; Wu, Min; Gerhard, Danielle; Shinohara, Ryota; Sliby, Alexa-Nicole; Chowdhury, Golam M. I. et al. (September 2021). «Cell-type specific modulation of NMDA receptors triggers antidepressant actions». Molecular Psychiatry 26 (9): 5097-5111. ISSN 1476-5578. PMID 32488125. doi:10.1038/s41380-020-0796-3.
Kato, Taro; Duman, Ronald S. (January 2020). «Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms». Pharmacology, Biochemistry, and Behavior 188: 172827. ISSN 1873-5177. PMID 31733218. doi:10.1016/j.pbb.2019.172827.

prnewswire.com (Global: 406^th place; Spanish: 666^th place)

FDA Grants Fast Track Designation to Naurex's Rapid-Acting Novel Antidepressant GLYX-13 http://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-naurexs-rapid-acting-novel-antidepressant-glyx-13-248174561.html
plc, Allergan. «Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD)». www.prnewswire.com (en inglés). Consultado el 13 de mayo de 2022.

reuters.com (Global: 49^th place; Spanish: 100^th place)

«Allergan's add-on treatment for depression fails late-stage studies». Reuters. 6 de marzo de 2019.

semanticscholar.org (Global: 11^th place; Spanish: 79^th place)

api.semanticscholar.org

Preskorn, Sheldon; Macaluso, Matthew; Mehra, D. O. Vishaal; Zammit, Gary; Moskal, Joseph R.; Burch, Ronald M.; GLYX-13 Clinical Study Group (March 2015). «Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent». Journal of Psychiatric Practice 21 (2): 140-149. ISSN 1538-1145. PMID 25782764. S2CID 36800194. doi:10.1097/01.pra.0000462606.17725.93.
Haring R, Stanton PK, Scheideler MA, Moskal JR (1991). «Glycine-like modulation of N-methyl-D-aspartate receptors by a monoclonal antibody that enhances long-term potentiation». J. Neurochem. 57 (1): 323-32. PMID 1828831. S2CID 37941813. doi:10.1111/j.1471-4159.1991.tb02131.x.
Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, Harris RB, Disterhoft JF (2005). «GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator». Neuropharmacology 49 (7): 1077-87. PMID 16051282. S2CID 7372648. doi:10.1016/j.neuropharm.2005.06.006.
Moskal, Joseph R.; Kuo, Amy G.; Weiss, Craig; Wood, Paul L.; O'Connor Hanson, Amy; Kelso, Stephen; Harris, Robert B.; Disterhoft, John F. (2005). «GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulator». Neuropharmacology 49 (7): 1077-87. PMID 16051282. S2CID 7372648. doi:10.1016/j.neuropharm.2005.06.006.
Stanton, Patric K.; Potter, Pamela E.; Aguilar, Jennifer; Decandia, Maria; Moskal, Joseph R. (2009). «Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13». NeuroReport 20 (13): 1193-7. PMID 19623090. S2CID 6269255. doi:10.1097/WNR.0b013e32832f5130.